Depressive symptoms
Conditions
Interventions
The group receiving combined cross-sequential treatment with a-iTBS and a-cTBS:There was a time interval between a-iTBS and a-cTBS combined with cross-sequential therapy
The combined cross-sequential treatment group of a-iTBS and a-cTBS without time intervals:There was no time interval between a-iTBS and a-cTBS combined with cross-sequential treatment
Sponsors
The Affiliated Kangning Hospital of Ningbo University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 18~65 years old; 2.Meets the diagnostic criteria for major depressive disorder as defined in the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V); 3. The total score of HAMD-24 items > 20 points; 4. right-handed; 5. The score on the Chinese version of the Beck Suicide Ideation Scale (BSI-CV) was >= 6 points; 6. The patient's physical examination, medical history, vital signs, hematuria and stool routine, liver and kidney function, electrolytes, electrocardiogram, electroencephalogram and other indicators were normal; 7. After fully understanding the safety of transcranial magnetic stimulation (TMS), willing to actively cooperate with the treatment, and signed informed consent by the person and his family.
Exclusion criteria
Exclusion criteria: 1. Age 65 years old; 2.Those with a history of severe physical illness and other psychoactive substances and depression caused by non-dependent substances; 3. The patient has metal or electronic devices built into the body, such as intracranial metal foreign bodies, cochlear implants, pacemakers, stents and other metal foreign bodies; 4. Have a risk of seizures, have previous craniocerebral disease, head trauma, alcoholism, electroencephalogram abnormalities, MRI evidence of brain structural abnormalities, or have a family history of epilepsy; 5. Acute suicide victims; 6. Those who have psychotic symptoms and need to take antipsychotic drugs; 7. ECT therapy within 2 months prior to enrollment; 8. Those who are pregnant, breastfeeding, or planning to become pregnant during the trial; 9. Refusal to sign informed consent.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Electroencephalographic features;3.0T magnetic resonance imaging (MRI) result ;Clinical scale score;Electromyography features;Near-infrared imaging (fNIRS) results; | — |
Countries
China
Contacts
Public ContactLi Xingxing
The Affiliated Kangning Hospital of Ningbo University
Outcome results
None listed